MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s10557-021-07155-5

Медицинская библиотека · Cardiovascular drugs and therapy · 2021

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.

Chouchana Laurent, Beeker Nathanaël, Garcelon Nicolas, Rance Bastien, Paris Nicolas, Salamanca Elisa, Polard Elisabeth, Burgun Anita, Treluyer Jean-Marc, Neuraz Antoine, AP-HP/Universities/Inserm COVID-19 research collaboration, AP-HP Covid CDR Initiative, and “Entrepôt de Données de Santé” AP-HP Consortium”

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

PURPOSE: The role of angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), or other antihypertensive agents in the case of Covid-19 remains controversial. We aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19.

METHODS

We performed a retrospective multicenter cohort study on patients hospitalized between February 1 and May 15, 2020. All patients had been followed up for at least 30 days.

RESULTS

Of the 8078 hospitalized patients for Covid-19, 3686 (45.6%) had hypertension and were included in the study. In this population, the median age was 75.4 (IQR, 21.5) years and 57.1% were male. Overall in-hospital 30-day mortality was 23.1%. The main antihypertensive pharmacological classes used were calcium channel blockers (CCB) (n=1624, 44.1%), beta-blockers (n=1389, 37.7%), ARB (n=1154, 31.3%), and ACEi (n=998, 27.1%). The risk of mortality was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers (aOR, 0.80 [0.67-0.95]) users and non-significant in ARB (aOR, 0.88 [0.72-1.06]) and ACEi (aOR, 0.83 [0.68-1.02]) users, compared to non-users. These results remain consistent for patients receiving CCB, beta-blocker, or ARB as monotherapies.

CONCLUSION

This large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines.

Для цитирования: Chouchana Laurent, Beeker Nathanaël, Garcelon Nicolas, Rance Bastien, Paris Nicolas, Salamanca Elisa, Polard Elisabeth, Burgun Anita, Treluyer Jean-Marc, Neuraz Antoine, AP-HP/Universities/Inserm COVID-19 research collaboration, AP-HP Covid CDR Initiative, and “Entrepôt de Données de Santé” AP-HP Consortium”. Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.. Cardiovascular drugs and therapy. 2021. DOI: 10.1007/s10557-021-07155-5.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.